Full-Time

Senior Manager

Quality Testing

Posted on 11/24/2025

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

No salary listed

St. Louis, MO, USA

In Person

Category
QA & Testing (1)
Requirements
  • BS in Chemistry, Chemical Engineering, related science or equivalent combination of education, experience, and competencies.
  • Minimum of 15 years related experience in Quality with 10 years management experience required. Proven personnel and project management history. Complete knowledge of pharmaceutical regulations including current GXP, GLP, or GMP requirements.
Responsibilities
  • Ensure key turnaround timelines for customer service and compliance requirements are achieved
  • Manage stability testing to achieve 100% on-time analysis for all stability protocol testing intervals
  • Serve as the primary liaison for method transfers into the QC organization
  • Accomplishes results through subordinate managers, supervisors, exempt specialist employees and non-exempt employees.
  • Provide overall leadership to QC groups regarding cGMP compliance improvement and enhancement
  • Serve as the Subject Matter Expert during compliance audits
  • Study and improve various Quality processes through increased efficiency or process flow using Lean Manufacturing and/ or Six Sigma philosophy of operation
  • Drive Quality consistency through revising or combining various analytical methods to ensure adequacy and quality with special emphasis on actual utility of methods under normal QC conditions
  • Work with all Quality managers, supervisors and analysts to address any laboratory concerns regarding safety, methods, procedures, or operation
  • Act as a liaison between the labs and manufacturing/ R&D in implementing special projects, production campaigns, or assist with validations or method transfers
  • Works with various reports and QC groups to ensure compliance to Environmental Health and Safety and departmental safety requirements and provide proactive leadership toward continuous improvement of safety operations in our laboratories
  • Ensure compliance with and oversee compendia affairs for SpecGx
Desired Qualifications
  • Excellent communication and leadership skills.
  • Ability to work in and promote a team environment.
  • Working knowledge of Six Sigma and/or Lean manufacturing tools.
  • Complete understanding and application of principles, concepts, practices, and standards within discipline.
  • Ability to lead and influence people.
  • Understanding of basic statistical principles, expert knowledge of validation principles, techniques, and regulatory expectations.
  • Knowledge of US and International pharmaceutical manufacturing regulations.
  • Exercises considerable latitude in determining technical objectives of assignment
  • Completed work is reviewed for desired results from a relatively long-term perspective
  • Bias toward change, management of change, and achievement of results

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Relocation Assistance

Company News

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.

INACTIVE